Icosavax, Inc.
NASDAQ: ICVX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Adam K. Simpson
- Employees
- 60
- Headquarters
- Seattle, United States
- IPO year
- 2021
- Market cap
- $769.0M
- Website
- https://icosavax.com
Loading ICVX…
Loading profile data…Frequently asked questions about ICVX
What does Icosavax, Inc. (ICVX) do?
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses. Its developmental portfolio includes several key vaccine candidates: IVX-121, a...
Where does ICVX trade?
Icosavax, Inc. (ICVX) trades on the NASDAQ Global Select.
What sector is ICVX in?
Icosavax, Inc. (ICVX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Icosavax, Inc.?
Adam K. Simpson is the chief executive officer of Icosavax, Inc. (ICVX).
Where is Icosavax, Inc. headquartered?
Icosavax, Inc. is headquartered in United States.
Does ICVX pay a dividend?
Icosavax, Inc. (ICVX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ICVX go public?
Icosavax, Inc. (ICVX) completed its initial public offering in 2021.